Amgen Neupogen
Executive Summary
PLA filing for the white blood cell growth factor was completed on Dec. 28. Amgen is seeking to market Neupogen (G-CSF, or granulocyte colony stimulating factor) as an adjunct to chemotherapy in certain cancers, primarily small cell lung cancer. The PLA includes data on more than 700 cancer patients from eight clinical centers in the U.S. and Europe.
You may also be interested in...
CureVac Could Be Third mRNA Vaccine Approval – But With A ‘Europe First’ Approach
Caught in a ‘vaccine nationalism’ crossfire a year ago, CureVac is now well placed to become a commercial entity – just as long as its mRNA platform can deliver.
Submitting A Non-COVID-19 Product For FDA Review? Then Take A Seat, It’s Gonna Be Awhile
Top US FDA device center officials Jeff Shuren and William Maisel said in a 15 April blog post that manufacturers should expect a delay in the review of new product submissions thanks to the pandemic. They noted that the agency also won’t be accepting certain IVD pre-submission requests until next year.
Prescience Point Capital Launches Proxy Fight To Change MiMedx's Board
Prescience Point Capital is trying to reshuffle the board of directors leading regenerative medicine company MiMedx, arguing the company’s current board has destroyed shareholder value. The company's tock is selling for about a third of its potential value, according to Prescience.